Wellcome Trust Award Lecture. Chromatin-modifying enzymes in transcription and cancer.
In recent years, our view of how gene expression is controlled has changed dramatically. The discovery of enzymes that modify histones has revealed that transcription is an enzymically driven process. Such modifications can recruit specific proteins and mediate chromatin changes that affect transcription either positively or negatively. Important biological pathways leading to cell proliferation are under the control of these enzymes, and several of them are found deregulated in cancer. The hope is that chromatin-modifying enzymes will be a rich source of targets for drug discovery.
Kouzarides
T
T
Wellcome Trust/Cancer Research UK Institute, University of Cambridge, Tennis Court Road, Cambridge, CB2 1QR, UK. tk106@mole.bio.ca.ac.uk
D000115:Acetylesterase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D002843:Chromatin / Q000378:metabolism*; D002868:Chromosomal Proteins, Non-Histone / Q000378:metabolism; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020868:Gene Silencing; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D008780:Methyltransferases / Q000378:metabolism; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics*; D010770:Phosphotransferases / Q000378:metabolism; D014158:Transcription, Genetic
D002843:Chromatin; D002868:Chromosomal Proteins, Non-Histone; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D008780:Methyltransferases; D010770:Phosphotransferases; D000115:Acetylesterase; D006655:Histone Deacetylases